Author

G. Dobreva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:gene regulatory network inference· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

S. Guenther· 2 shared A. Mehta· 1 shared A. Papapetropoulos· 1 shared A. Romero· 1 shared A. Tresch· 1 shared A. Weigert· 1 shared B. Bassaly· 1 shared D. John· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

S. Guenther

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A novel role for cystathionine gamma lyase in the control of p53: impact on endothelial senescence and metabolic reprograming

J. Hu, M. S. Leisegang, M. Looso, G. Dumbovic, J. Wittig, M.-K. Drekolia, S. Guenther, D. John, M. Siragusa, S. Zukunft, J. Oo, I. Wittig, S. Hille, A. Weigert, S. Knapp, , S. I. Bibli

This paper identifies CSE-p53 interaction as a regulator of endothelial cell senescence and metabolic reprogramming in aging, showing that restoring this interaction can prevent senescence and promote vascular repair.

bioRxiv · Sep 5, 2022 · PreprintCell Biology

Extracellular vesicles induce aggressive lung cancervia non-canonical integrin-EGFR-KRAS signaling

K. Rubio, A. Romero, P. Sarvari, S. Guenther, A. Mehta, B. Bassaly, P. Braubach, G. Dobreva, M. Wygrecka, S. Gattenloehner, T. Braun, A. Tresch, J. Graumann, G. Barreto

This study identifies a non-canonical ITGB2 signaling pathway that activates EGFR and RAS/MAPK/ERK in SCLC, leading to aggressive tumor behavior and resistance to EGFR inhibitors.

bioRxiv · Aug 16, 2022Cancer Biology